Exclusive By Ike Swetlitz Mylan offered EpiPen discounts to states in exchange for privileged status, documents show
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Merck and Scottish government conspired to trash environmental study
Pharmalot By Ed Silverman Mylan refuses to testify at Senate hearing about EpiPen rebates to Medicaid
Pharmalot By Ed Silverman Hospitals are itching for a share of the Mylan settlement over Medicaid rebates
Pharmalot By Ed Silverman West Virginia AG vows to reject ‘woefully deficient’ Mylan deal with the feds
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Drug stocks hurt by fears that price hikes are abating
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Senator to hold hearing on Mylan’s Medicaid settlement
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Pfizer will sell a biosimilar version of Remicade next month
The Pharmalot View By Ed Silverman Health officials should reject latest gambit by EpiPen maker to feed at the public trough
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Some docs say more patients want do-it-yourself EpiPens
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Chicago can proceed with lawsuit against opioid drug makers
Pharmalot By Ed Silverman Feds slam Mylan for misclassifying EpiPen, with ‘financial consequences’ to Medicaid
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Novo Nordisk cutting 1,000 jobs amid diabetes drug price war